1138PD - Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)

J.S Ross,M.E Goldberg,L.A Albacker,L.M Gay,V Agarwala,J.A Elvin,J-A Vergilio,J Suh,S Ramkissoon,E Severson,S Daniel,S.M Ali,A.B Schrock,G.M Frampton,D Fabrizio,V.A Miller,G Singal,A Abernethy,P.J Stephens

doi:10.1093/annonc/mdx376.004

1138PD - Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)

J.S Ross, M.E Goldberg + Show 17 more

Open Access

https://doi.org/10.1093/annonc/mdx376.004

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2017
Citations: 7	License type: elsevier-specific: oa user license

Affiliation: Flatiron Health (United States)

#Immune Checkpoint Inhibitor #Comprehensive Genomic Profiling + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1138PD - Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)

Full Text